APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Malignant Mesothelioma Therapeutic

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).

Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.

Selected research

Market Analysis & Forecast

Global Malignant Mesothelioma Therapeutic Market Analysis and Forecast 2026-2032

Report ID 173894660231 December 2025192 pages

Choose your research edition.

Industry ResearchMalignant Mesothelioma Therapeutic Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Malignant Mesothelioma Therapeutic Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Malignant Mesothelioma Therapeutic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Malignant Mesothelioma Therapeutic Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Malignant Mesothelioma Therapeutic Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).

Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.

The classification of Malignant Mesothelioma Therapeutic includes Pemetrexed, Cisplatin and others. The proportion of Pemetrexed in 2019 approaches 50%. Malignant Mesothelioma Therapeutic is mostly used for Pleural Mesothelioma, and the proportion in 2019 is about 80%. Europe is the largest market, with a sales market share above 50% in 2019. Following Europe, Asia Pacific is the second largest sales place with the sales market share of above 1/5. Market competition is intense. Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.

Read the full market overview

Report Includes

This report presents an overview of global market for Malignant Mesothelioma Therapeutic, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Malignant Mesothelioma Therapeutic, also provides the revenue of main regions and countries. Of the upcoming market potential for Malignant Mesothelioma Therapeutic, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Malignant Mesothelioma Therapeutic revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Malignant Mesothelioma Therapeutic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Malignant Mesothelioma Therapeutic revenue, projected growth trends, production technology, application and end-user industry.

Malignant Mesothelioma Therapeutic Segment by Company

Eli Lilly

Teva

Sanofi

Bristol-Myers Squibb

Pfizer

Roche

Merck

Ono Pharmaceutical

Mylan

Fresenius Kabi

Sun Pharmaceuticals

Malignant Mesothelioma Therapeutic Segment by Type

Pemetrexed

Cisplatin

Others

Malignant Mesothelioma Therapeutic Segment by Application

Pleural Mesothelioma

Peritoneal Mesothelioma

Others

Malignant Mesothelioma Therapeutic Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Malignant Mesothelioma Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Malignant Mesothelioma Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Malignant Mesothelioma Therapeutic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Malignant Mesothelioma Therapeutic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Malignant Mesothelioma Therapeutic company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Malignant Mesothelioma Therapeutic revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Pemetrexed Major Player Table 3. Cisplatin Major Player Table 4. Others Major Player Table 5. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Pleural Mesothelioma Major Player Table 7. Peritoneal Mesothelioma Major Player Table 8. Others Major Player Table 9. Malignant Mesothelioma Therapeutic Industry Trends Table 10. Malignant Mesothelioma Therapeutic Industry Drivers Table 11. Malignant Mesothelioma Therapeutic Industry Opportunities and Challenges Table 12. Malignant Mesothelioma Therapeutic Industry Restraints Table 13. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Malignant Mesothelioma Therapeutic Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Malignant Mesothelioma Therapeutic Market Share by Region (2021-2026) Table 16. Global Malignant Mesothelioma Therapeutic Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Malignant Mesothelioma Therapeutic Market Share by Region (2027-2032) Table 18. Global Malignant Mesothelioma Therapeutic Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Players (2021-2026) Table 20. Global Malignant Mesothelioma Therapeutic Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Malignant Mesothelioma Therapeutic Key Players Headquarters & Area Served Table 22. Global Malignant Mesothelioma Therapeutic Players, Product Type & Application Table 23. Global Malignant Mesothelioma Therapeutic Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Malignant Mesothelioma Therapeutic by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Malignant Mesothelioma Therapeutic Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Malignant Mesothelioma Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Malignant Mesothelioma Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2021-2026) Table 30. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2027-2032) Table 31. Global Malignant Mesothelioma Therapeutic Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Malignant Mesothelioma Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Malignant Mesothelioma Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2021-2026) Table 35. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2027-2032) Table 36. Eli Lilly Company Information Table 37. Eli Lilly Business Overview Table 38. Eli Lilly Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Eli Lilly Malignant Mesothelioma Therapeutic Product Portfolio Table 40. Eli Lilly Recent Development Table 41. Teva Company Information Table 42. Teva Business Overview Table 43. Teva Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Teva Malignant Mesothelioma Therapeutic Product Portfolio Table 45. Teva Recent Development Table 46. Sanofi Company Information Table 47. Sanofi Business Overview Table 48. Sanofi Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Sanofi Malignant Mesothelioma Therapeutic Product Portfolio Table 50. Sanofi Recent Development Table 51. Bristol-Myers Squibb Company Information Table 52. Bristol-Myers Squibb Business Overview Table 53. Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Product Portfolio Table 55. Bristol-Myers Squibb Recent Development Table 56. Pfizer Company Information Table 57. Pfizer Business Overview Table 58. Pfizer Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Pfizer Malignant Mesothelioma Therapeutic Product Portfolio Table 60. Pfizer Recent Development Table 61. Roche Company Information Table 62. Roche Business Overview Table 63. Roche Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Roche Malignant Mesothelioma Therapeutic Product Portfolio Table 65. Roche Recent Development Table 66. Merck Company Information Table 67. Merck Business Overview Table 68. Merck Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Merck Malignant Mesothelioma Therapeutic Product Portfolio Table 70. Merck Recent Development Table 71. Ono Pharmaceutical Company Information Table 72. Ono Pharmaceutical Business Overview Table 73. Ono Pharmaceutical Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Ono Pharmaceutical Malignant Mesothelioma Therapeutic Product Portfolio Table 75. Ono Pharmaceutical Recent Development Table 76. Mylan Company Information Table 77. Mylan Business Overview Table 78. Mylan Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Mylan Malignant Mesothelioma Therapeutic Product Portfolio Table 80. Mylan Recent Development Table 81. Fresenius Kabi Company Information Table 82. Fresenius Kabi Business Overview Table 83. Fresenius Kabi Malignant Mesothelioma Therapeutic Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Fresenius Kabi Malignant Mesothelioma Therapeutic Product Portfolio Table 85. Fresenius Kabi Recent Development Table 86. Sun Pharmaceuticals Company Information Table 87. Sun Pharmaceuticals Business Overview Table 88. Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Product Portfolio Table 90. Sun Pharmaceuticals Recent Development Table 91. North America Malignant Mesothelioma Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 92. North America Malignant Mesothelioma Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 93. North America Malignant Mesothelioma Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 94. North America Malignant Mesothelioma Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 95. North America Malignant Mesothelioma Therapeutic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 96. North America Malignant Mesothelioma Therapeutic Revenue by Country (2021-2026) & (US$ Million) Table 97. North America Malignant Mesothelioma Therapeutic Revenue by Country (US$ Million) & (2027-2032) Table 98. Europe Malignant Mesothelioma Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 99. Europe Malignant Mesothelioma Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 100. Europe Malignant Mesothelioma Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 101. Europe Malignant Mesothelioma Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 102. Europe Malignant Mesothelioma Therapeutic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 103. Europe Malignant Mesothelioma Therapeutic Revenue by Country (2021-2026) & (US$ Million) Table 104. Europe Malignant Mesothelioma Therapeutic Revenue by Country (US$ Million) & (2027-2032) Table 105. China Malignant Mesothelioma Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 106. China Malignant Mesothelioma Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 107. China Malignant Mesothelioma Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 108. China Malignant Mesothelioma Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 109. Asia Malignant Mesothelioma Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 110. Asia Malignant Mesothelioma Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 111. Asia Malignant Mesothelioma Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 112. Asia Malignant Mesothelioma Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 113. Asia Malignant Mesothelioma Therapeutic Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 114. Asia Malignant Mesothelioma Therapeutic Revenue by Region (US$ Million) & (2021-2026) Table 115. Asia Malignant Mesothelioma Therapeutic Revenue by Region (US$ Million) & (2027-2032) Table 116. SAMEA Malignant Mesothelioma Therapeutic Revenue by Type (2021-2026) & (US$ Million) Table 117. SAMEA Malignant Mesothelioma Therapeutic Revenue by Type (2027-2032) & (US$ Million) Table 118. SAMEA Malignant Mesothelioma Therapeutic Revenue by Application (2021-2026) & (US$ Million) Table 119. SAMEA Malignant Mesothelioma Therapeutic Revenue by Application (2027-2032) & (US$ Million) Table 120. SAMEA Malignant Mesothelioma Therapeutic Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. SAMEA Malignant Mesothelioma Therapeutic Revenue by Country (2021-2026) & (US$ Million) Table 122. SAMEA Malignant Mesothelioma Therapeutic Revenue by Country (US$ Million) & (2027-2032) Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. Malignant Mesothelioma Therapeutic Image Figure 2. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Malignant Mesothelioma Therapeutic Market Size Share 2021 VS 2025 VS 2032 Figure 4. Pemetrexed Image Figure 5. Cisplatin Image Figure 6. Others Image Figure 7. Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Malignant Mesothelioma Therapeutic Market Size Share 2021 VS 2025 VS 2032 Figure 9. Pleural Mesothelioma Image Figure 10. Peritoneal Mesothelioma Image Figure 11. Others Image Figure 12. Global Malignant Mesothelioma Therapeutic Market Size (US$ Million) & (2021-2032) Figure 13. Global Malignant Mesothelioma Therapeutic Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Malignant Mesothelioma Therapeutic Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Malignant Mesothelioma Therapeutic Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Malignant Mesothelioma Therapeutic Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Malignant Mesothelioma Therapeutic Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2021-2032) Figure 20. Global Malignant Mesothelioma Therapeutic Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2021-2032) Figure 23. North America Malignant Mesothelioma Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Malignant Mesothelioma Therapeutic Revenue Share by Type (2021-2032) Figure 25. North America Malignant Mesothelioma Therapeutic Revenue Share by Application (2021-2032) Figure 26. North America Malignant Mesothelioma Therapeutic Revenue Share by Country (2021-2032) Figure 27. United States Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Malignant Mesothelioma Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Malignant Mesothelioma Therapeutic Revenue Share by Type (2021-2032) Figure 32. Europe Malignant Mesothelioma Therapeutic Revenue Share by Application (2021-2032) Figure 33. Europe Malignant Mesothelioma Therapeutic Revenue Share by Country (2021-2032) Figure 34. Germany Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Malignant Mesothelioma Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Malignant Mesothelioma Therapeutic Revenue Share by Type (2021-2032) Figure 44. China Malignant Mesothelioma Therapeutic Revenue Share by Application (2021-2032) Figure 45. Asia Malignant Mesothelioma Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Malignant Mesothelioma Therapeutic Revenue Share by Type (2021-2032) Figure 47. Asia Malignant Mesothelioma Therapeutic Revenue Share by Application (2021-2032) Figure 48. Asia Malignant Mesothelioma Therapeutic Revenue Share by Region (2021-2032) Figure 49. Japan Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Malignant Mesothelioma Therapeutic Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Malignant Mesothelioma Therapeutic Revenue Share by Type (2021-2032) Figure 57. SAMEA Malignant Mesothelioma Therapeutic Revenue Share by Application (2021-2032) Figure 58. SAMEA Malignant Mesothelioma Therapeutic Revenue Share by Country (2021-2032) Figure 59. Brazil Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Malignant Mesothelioma Therapeutic Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Pemetrexed
  • Cisplatin
  • Others
Applications
  • Pleural Mesothelioma
  • Peritoneal Mesothelioma
  • Others
Companies covered
  • Eli Lilly
  • Teva
  • Sanofi
  • Bristol-Myers Squibb
  • Pfizer
  • Roche
  • Merck
  • Ono Pharmaceutical
  • Mylan
  • Fresenius Kabi
  • Sun Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Malignant Mesothelioma Therapeutic Market by Type
  3. 1.2.1 Global Malignant Mesothelioma Therapeutic Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Pemetrexed
  5. 1.2.3 Cisplatin
  6. 1.2.4 Others
  7. 1.3 Malignant Mesothelioma Therapeutic Market by Application
  8. 1.3.1 Global Malignant Mesothelioma Therapeutic Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Pleural Mesothelioma
  10. 1.3.3 Peritoneal Mesothelioma
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Malignant Mesothelioma Therapeutic Market Dynamics
  1. 2.1 Malignant Mesothelioma Therapeutic Industry Trends
  2. 2.2 Malignant Mesothelioma Therapeutic Industry Drivers
  3. 2.3 Malignant Mesothelioma Therapeutic Industry Opportunities and Challenges
  4. 2.4 Malignant Mesothelioma Therapeutic Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Malignant Mesothelioma Therapeutic Market Perspective (2021-2032)
  2. 3.2 Global Malignant Mesothelioma Therapeutic Growth Trends by Region
  3. 3.2.1 Global Malignant Mesothelioma Therapeutic Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Malignant Mesothelioma Therapeutic Market Size by Region (2021-2026)
  5. 3.2.3 Global Malignant Mesothelioma Therapeutic Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Malignant Mesothelioma Therapeutic Revenue by Players
  2. 4.1.1 Global Malignant Mesothelioma Therapeutic Revenue by Players (2021-2026)
  3. 4.1.2 Global Malignant Mesothelioma Therapeutic Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Malignant Mesothelioma Therapeutic Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Malignant Mesothelioma Therapeutic Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Malignant Mesothelioma Therapeutic Key Players Headquarters & Area Served
  7. 4.4 Global Malignant Mesothelioma Therapeutic Players, Product Type & Application
  8. 4.5 Global Malignant Mesothelioma Therapeutic Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Malignant Mesothelioma Therapeutic Market CR5 and HHI
  11. 4.6.3 2025 Malignant Mesothelioma Therapeutic Tier 1, Tier 2, and Tier 3
5 Malignant Mesothelioma Therapeutic Market Size by Type
  1. 5.1 Global Malignant Mesothelioma Therapeutic Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Malignant Mesothelioma Therapeutic Revenue by Type (2021-2032)
  3. 5.3 Global Malignant Mesothelioma Therapeutic Revenue Market Share by Type (2021-2032)
6 Malignant Mesothelioma Therapeutic Market Size by Application
  1. 6.1 Global Malignant Mesothelioma Therapeutic Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Malignant Mesothelioma Therapeutic Revenue by Application (2021-2032)
  3. 6.3 Global Malignant Mesothelioma Therapeutic Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Eli Lilly
  2. 7.1.1 Eli Lilly Company Information
  3. 7.1.2 Eli Lilly Business Overview
  4. 7.1.3 Eli Lilly Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Eli Lilly Malignant Mesothelioma Therapeutic Product Portfolio
  6. 7.1.5 Eli Lilly Recent Developments
  7. 7.2 Teva
  8. 7.2.1 Teva Company Information
  9. 7.2.2 Teva Business Overview
  10. 7.2.3 Teva Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Teva Malignant Mesothelioma Therapeutic Product Portfolio
  12. 7.2.5 Teva Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Malignant Mesothelioma Therapeutic Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Bristol-Myers Squibb
  20. 7.4.1 Bristol-Myers Squibb Company Information
  21. 7.4.2 Bristol-Myers Squibb Business Overview
  22. 7.4.3 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Product Portfolio
  24. 7.4.5 Bristol-Myers Squibb Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Malignant Mesothelioma Therapeutic Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Roche
  32. 7.6.1 Roche Company Information
  33. 7.6.2 Roche Business Overview
  34. 7.6.3 Roche Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Roche Malignant Mesothelioma Therapeutic Product Portfolio
  36. 7.6.5 Roche Recent Developments
  37. 7.7 Merck
  38. 7.7.1 Merck Company Information
  39. 7.7.2 Merck Business Overview
  40. 7.7.3 Merck Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Merck Malignant Mesothelioma Therapeutic Product Portfolio
  42. 7.7.5 Merck Recent Developments
  43. 7.8 Ono Pharmaceutical
  44. 7.8.1 Ono Pharmaceutical Company Information
  45. 7.8.2 Ono Pharmaceutical Business Overview
  46. 7.8.3 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Product Portfolio
  48. 7.8.5 Ono Pharmaceutical Recent Developments
  49. 7.9 Mylan
  50. 7.9.1 Mylan Company Information
  51. 7.9.2 Mylan Business Overview
  52. 7.9.3 Mylan Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Mylan Malignant Mesothelioma Therapeutic Product Portfolio
  54. 7.9.5 Mylan Recent Developments
  55. 7.10 Fresenius Kabi
  56. 7.10.1 Fresenius Kabi Company Information
  57. 7.10.2 Fresenius Kabi Business Overview
  58. 7.10.3 Fresenius Kabi Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Fresenius Kabi Malignant Mesothelioma Therapeutic Product Portfolio
  60. 7.10.5 Fresenius Kabi Recent Developments
  61. 7.11 Sun Pharmaceuticals
  62. 7.11.1 Sun Pharmaceuticals Company Information
  63. 7.11.2 Sun Pharmaceuticals Business Overview
  64. 7.11.3 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Product Portfolio
  66. 7.11.5 Sun Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Malignant Mesothelioma Therapeutic Revenue (2021-2032)
  2. 8.2 North America Malignant Mesothelioma Therapeutic Revenue by Type (2021-2032)
  3. 8.2.1 North America Malignant Mesothelioma Therapeutic Revenue by Type (2021-2026)
  4. 8.2.2 North America Malignant Mesothelioma Therapeutic Revenue by Type (2027-2032)
  5. 8.3 North America Malignant Mesothelioma Therapeutic Revenue Share by Type (2021-2032)
  6. 8.4 North America Malignant Mesothelioma Therapeutic Revenue by Application (2021-2032)
  7. 8.4.1 North America Malignant Mesothelioma Therapeutic Revenue by Application (2021-2026)
  8. 8.4.2 North America Malignant Mesothelioma Therapeutic Revenue by Application (2027-2032)
  9. 8.5 North America Malignant Mesothelioma Therapeutic Revenue Share by Application (2021-2032)
  10. 8.6 North America Malignant Mesothelioma Therapeutic Revenue by Country
  11. 8.6.1 North America Malignant Mesothelioma Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Malignant Mesothelioma Therapeutic Revenue by Country (2021-2026)
  13. 8.6.3 North America Malignant Mesothelioma Therapeutic Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Malignant Mesothelioma Therapeutic Revenue (2021-2032)
  2. 9.2 Europe Malignant Mesothelioma Therapeutic Revenue by Type (2021-2032)
  3. 9.2.1 Europe Malignant Mesothelioma Therapeutic Revenue by Type (2021-2026)
  4. 9.2.2 Europe Malignant Mesothelioma Therapeutic Revenue by Type (2027-2032)
  5. 9.3 Europe Malignant Mesothelioma Therapeutic Revenue Share by Type (2021-2032)
  6. 9.4 Europe Malignant Mesothelioma Therapeutic Revenue by Application (2021-2032)
  7. 9.4.1 Europe Malignant Mesothelioma Therapeutic Revenue by Application (2021-2026)
  8. 9.4.2 Europe Malignant Mesothelioma Therapeutic Revenue by Application (2027-2032)
  9. 9.5 Europe Malignant Mesothelioma Therapeutic Revenue Share by Application (2021-2032)
  10. 9.6 Europe Malignant Mesothelioma Therapeutic Revenue by Country
  11. 9.6.1 Europe Malignant Mesothelioma Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Malignant Mesothelioma Therapeutic Revenue by Country (2021-2026)
  13. 9.6.3 Europe Malignant Mesothelioma Therapeutic Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Malignant Mesothelioma Therapeutic Revenue (2021-2032)
  2. 10.2 China Malignant Mesothelioma Therapeutic Revenue by Type (2021-2032)
  3. 10.2.1 China Malignant Mesothelioma Therapeutic Revenue by Type (2021-2026)
  4. 10.2.2 China Malignant Mesothelioma Therapeutic Revenue by Type (2027-2032)
  5. 10.3 China Malignant Mesothelioma Therapeutic Revenue Share by Type (2021-2032)
  6. 10.4 China Malignant Mesothelioma Therapeutic Revenue by Application (2021-2032)
  7. 10.4.1 China Malignant Mesothelioma Therapeutic Revenue by Application (2021-2026)
  8. 10.4.2 China Malignant Mesothelioma Therapeutic Revenue by Application (2027-2032)
  9. 10.5 China Malignant Mesothelioma Therapeutic Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Malignant Mesothelioma Therapeutic Revenue (2021-2032)
  2. 11.2 Asia Malignant Mesothelioma Therapeutic Revenue by Type (2021-2032)
  3. 11.2.1 Asia Malignant Mesothelioma Therapeutic Revenue by Type (2021-2026)
  4. 11.2.2 Asia Malignant Mesothelioma Therapeutic Revenue by Type (2027-2032)
  5. 11.3 Asia Malignant Mesothelioma Therapeutic Revenue Share by Type (2021-2032)
  6. 11.4 Asia Malignant Mesothelioma Therapeutic Revenue by Application (2021-2032)
  7. 11.4.1 Asia Malignant Mesothelioma Therapeutic Revenue by Application (2021-2026)
  8. 11.4.2 Asia Malignant Mesothelioma Therapeutic Revenue by Application (2027-2032)
  9. 11.5 Asia Malignant Mesothelioma Therapeutic Revenue Share by Application (2021-2032)
  10. 11.6 Asia Malignant Mesothelioma Therapeutic Revenue by Country
  11. 11.6.1 Asia Malignant Mesothelioma Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Malignant Mesothelioma Therapeutic Revenue by Country (2021-2026)
  13. 11.6.3 Asia Malignant Mesothelioma Therapeutic Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Malignant Mesothelioma Therapeutic Revenue (2021-2032)
  2. 12.2 SAMEA Malignant Mesothelioma Therapeutic Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Malignant Mesothelioma Therapeutic Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Malignant Mesothelioma Therapeutic Revenue by Type (2027-2032)
  5. 12.3 SAMEA Malignant Mesothelioma Therapeutic Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Malignant Mesothelioma Therapeutic Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Malignant Mesothelioma Therapeutic Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Malignant Mesothelioma Therapeutic Revenue by Application (2027-2032)
  9. 12.5 SAMEA Malignant Mesothelioma Therapeutic Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Malignant Mesothelioma Therapeutic Revenue by Country
  11. 12.6.1 SAMEA Malignant Mesothelioma Therapeutic Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Malignant Mesothelioma Therapeutic Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Malignant Mesothelioma Therapeutic Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst